Patents by Inventor Stuart C. Chaffee

Stuart C. Chaffee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8557996
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. The compounds have a general Formula I wherein A1, A2, A3, A4, R1 and R2 are defined herein. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: October 15, 2013
    Assignee: Amgen Inc.
    Inventors: Stuart C. Chaffee, Brian K. Albrecht
  • Patent number: 8476434
    Abstract: The present invention relates to chemical compounds having a general formula I wherein A, B, D, E, G, H1-5 and R1-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compounds are capable of modulating kinase enzymes thereby influencing the process of angiogenesis and treating angiogenesis-related diseases and other proliferative disorders, including cancer and inflammation. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of protein kinases.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: July 2, 2013
    Assignee: Amgen Inc.
    Inventors: Stephanie D. Geuns-Meyer, Brian L. Hodous, Stuart C. Chaffee, Paul Tempest, Ning Xi, Phillip R. Olivieri, Joseph L. Kim, Steven Bellon, Xiaotian Zhu, Yuan Cheng, Brian K. Albrecht, Vinod F. Patel, Victor J. Cee, Karina Romero, Hanh Nho Nguyen, Holly L. Deak, Rebecca E. Johnson
  • Patent number: 8178557
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: June 9, 2008
    Date of Patent: May 15, 2012
    Assignee: Amgen Inc.
    Inventors: Michele Potashman, Tae-Seong Kim, Steven Bellon, Shon Booker, Yuan Cheng, Joseph L. Kim, Andrew Tasker, Ning Xi, Shimin Xu, Jean-Christophe Harmange, George Borg, Matthew Weiss, Brian L. Hodous, Russell Graceffa, William H. Buckner, Craig E. Masse, Deborah Choquette, Matthew W. Martin, Julie Germain, Lucian V. DiPietro, Stuart C. Chaffee, Joseph J. Nunes, John L. Buchanan, David C. McGowan, Douglas A. Whittington, Gregory J. Habgood, Vinod F. Patel, Daniel La
  • Patent number: 8163766
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: April 24, 2012
    Assignee: Amgen Inc.
    Inventors: Wenge Zhong, Stephen A. Hitchcock, Vinod F. Patel, Yuan Cheng, Michael Croghan, Randall W. Hungate, Daniel La, Patricia Lopez, Matthew K. Kaller, Holger Monenschein, Thomas Nguyen, Thomas Nixey, Lewis Pennington, Matthew Weiss, Ted Judd, Russell Graceffa, Qiufen Xue, Charles Kreiman, Brian K. Albrecht, Denise Lyn Andersen, Michael Bartberger, James Brown, Ryan Brown, Stuart C. Chaffee, Scott Harried, Craig Masse, Bryant Yang
  • Publication number: 20110201602
    Abstract: The present invention relates to chemical compounds having a general formula I wherein A, B, D, E, G, H1-5 and R1-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compounds are capable of modulating kinase enzymes thereby influencing the process of angiogenesis and treating angiogenesis-related diseases and other proliferative disorders, including cancer and inflammation. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of protein kinases.
    Type: Application
    Filed: November 22, 2010
    Publication date: August 18, 2011
    Applicant: Amgen Inc.
    Inventors: Stephanie D. GEUNS-MEYER, Brian L. HODOUS, Stuart C. CHAFFEE, Paul TEMPEST, Phillip R. OLIVIERI, Rebecca E. JOHNSON, Brian K. ALBRECHT, Vinod F. PATEL, Victor J. CEE, Joseph L. KIM, Steven BELLON, Xiaotian ZHU, Yuan CHENG, Ning XI, Karina ROMERO, Hanh Nho NGUYEN, Holly L. DEAK
  • Patent number: 7973047
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, W, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.
    Type: Grant
    Filed: May 13, 2010
    Date of Patent: July 5, 2011
    Assignee: Amgen Inc.
    Inventors: Wenge Zhong, Stephen Hitchcock, Brian K. Albrecht, Michael D. Bartberger, James Brown, Ryan Brown, Stuart C. Chaffee, Yuan Cheng, Michael Croghan, Russell Graceffa, Scott Harried, Dean Hickman, Daniel Horne, Randall Hungate, Ted Judd, Matthew Kaller, Charles Kreiman, Daniel La, Patricia Lopez, Craig E. Masse, Thomas Nixey, Vinod F. Patel, Lewis Pennington, Matthew Weiss, Qiufen Xue, Bryant Yang, Holger Monenschein, Thomas Nguyen
  • Publication number: 20110118250
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.
    Type: Application
    Filed: October 21, 2010
    Publication date: May 19, 2011
    Applicant: Amgen Inc.
    Inventors: Brian K. Albrecht, Denise Lyn Andersen, Michael Bartberger, James Brown, Ryan Brown, Stuart C. Chaffee, Yuan Cheng, Michael Croghan, Russell Graceffa, Scott Harried, Stephen Hitchcock, Randall Hungate, Ted Judd, Matthew Kaller, Charles Kreiman, Daniel La, Patricia Lopez, Craig Masse, Holger Monenschein, Thomas Nguyen, Thomas Nixey, Vinod F. Patel, Lewis Pennington, Matthew Weiss, Qiufen Xue, Bryant Yang, Wenge Zhong
  • Patent number: 7880000
    Abstract: The present invention relates to chemical compounds having a general formula I wherein A, B, D, E, G, H1-5 and R1-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compounds are capable of modulating kinase enzymes thereby influencing the process of angiogenesis and treating angiogenesis-related diseases and other poliferative disorders, including cancer and inflammation. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of protein kinases.
    Type: Grant
    Filed: May 9, 2005
    Date of Patent: February 1, 2011
    Assignee: Amgen Inc.
    Inventors: Stephanie D. Geuns-Meyer, Brian L. Hodous, Stuart C. Chaffee, Paul A. Tempest, Philip R. Olivieri, Rebecca E. Johnson, Brian K. Albrecht, Vinod F. Patel, Victor J. Cee, Joseph L. Kim, Steven Bellon, Xiaotian Zhu, Yuan Cheng, Ning Xi, Karina Romero, Hanh Nho Nguyen, Holly L. Deak
  • Patent number: 7872009
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: January 18, 2011
    Assignee: Amgen Inc.
    Inventors: Brian K. Albrecht, Denise Lyn Andersen, Michael Bartberger, James Brown, Ryan Brown, Stuart C. Chaffee, Yuan Cheng, Michael Croghan, Russell Graceffa, Scott Harried, Stephen Hitchcock, Randall Hungate, Ted Judd, Matthew Kaller, Charles Kreiman, Daniel La, Patricia Lopez, Craig Masse, Holger Monenschein, Thomas Nguyen, Thomas Nixey, Vinod F. Patel, Lewis Pennington, Matthew Weiss, Qiufen Xue, Bryant Yang, Wenge Zhong
  • Patent number: 7838676
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein R1, W, B, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: November 23, 2010
    Assignee: Amgen Inc.
    Inventors: Qiufen Xue, Brian K. Albrecht, Denise Lyn Andersen, Michael Bartberger, James Brown, Ryan Brown, Stuart C. Chaffee, Yuan Cheng, Michael Croghan, Russell Graceffa, Scott Harried, Stephen Hitchcock, Randall Hungate, Ted Judd, Matthew Kaller, Charles Kreiman, Daniel La, Patricia Lopez, Craig Masse, Holger Monenschein, Thomas Nguyen, Thomas Nixey, Vinod F. Patel, Lewis Pennington, Matthew Weiss, Bryant Yang, Wenge Zhong
  • Publication number: 20100234373
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including autoimmune disease and inflammation. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, L, R1, R2 and R3 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of the present invention, methods of use such as treatment of Lck and/or c-Kit kinase mediated diseases by administering the compounds of the invention, or compositions including one or more compounds of the invention, and intermediates and processes useful for the preparation of compounds of the present invention.
    Type: Application
    Filed: May 26, 2010
    Publication date: September 16, 2010
    Applicant: Amgen Inc.
    Inventors: Erin F. Dimauro, Jean E. Bemis, Stuart C. Chaffee, Ning Chen, Essa Hu, Roxanne Kunz, Matthew W. Martin, David C. McGowan, Shannon Rumfelt
  • Publication number: 20100222338
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, W, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.
    Type: Application
    Filed: May 13, 2010
    Publication date: September 2, 2010
    Inventors: Wenge Zhong, Stephen Hitchcock, Brian K. Albrecht, Michael D. Bartberger, James Brown, Ryan Brown, Stuart C. Chaffee, Yuan Cheng, Michael Croghan, Russell Graceffa, Scott Harried, Dean Hickman, Daniel Horne, Randall Hungate, Ted Judd, Matthew Kaller, Charles Kreiman, Daniel La, Patricia Lopez, Craig E. Masse, Thomas Nixey, Vinod F. Patel, Lewis Pennington, Matthew Weiss, Qiufen Xue, Bryant Yang, Holger Monenschein, Thomas Nguyen
  • Patent number: 7776869
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. The compounds have a general Formula I wherein A1, A2, A3, A4, R1 and R2 are defined herein. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: August 17, 2010
    Assignee: Amgen Inc.
    Inventors: Stuart C. Chaffee, Brian K. Albrecht, Brian L. Hodous, Matthew W. Martin, David C. McGowan, Erin F. DiMauro, Gade Reddy, Victor J. Cee, Philip R. Olivieri, Anthony Reed, Karina Romero
  • Patent number: 7754717
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including autoimmune disease and inflammation. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, L, R1, R2 and R3 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of the present invention, methods of use such as treatment of Lck and/or c-Kit kinase mediated diseases by administering the compounds of the invention, or compositions including one or more compounds of the invention, and intermediates and processes useful for the preparation of compounds of the present invention.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: July 13, 2010
    Assignee: Amgen Inc.
    Inventors: Erin F. Dimauro, Jean E. Bemis, Stuart C. Chaffee, Ning Chen, Essa Hu, Roxanne Kunz, Matthew W. Martin, David C. McGowan, Shannon Rumfelt
  • Patent number: 7745484
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, W, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.
    Type: Grant
    Filed: November 10, 2006
    Date of Patent: June 29, 2010
    Assignee: Amgen Inc.
    Inventors: Wenge Zhong, Stephen Hitchcock, Brian K. Albrecht, Michael D. Bartberger, James Brown, Ryan Brown, Stuart C. Chaffee, Yuan Cheng, Michael Croghan, Russell Graceffa, Scott Harried, Dean Hickman, Dan Horne, Randall Hungate, Ted Judd, Matthew Kaller, Charles Kreiman, Daniel La, Patricia Lopez, Craig Masse, Holger Monenschein, Thomas Nguyen, Thomas Nixey, Vinod F. Patel, Lewis Pennington, Matthew Weiss, Qiufen Xue, Bryant Yang
  • Publication number: 20100160283
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. The compounds have a general Formula I wherein A1, A2, A3, A4, R1 and R2 are defined herein. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention.
    Type: Application
    Filed: March 2, 2010
    Publication date: June 24, 2010
    Applicant: Amgen Inc.
    Inventors: Stuart C. Chaffee, Brian K. Albrecht, Brian L. Hodous, Matthew W. Martin, David C. McGowan, Erin F. DiMauro, Gade Reddy, Victor J. Cee, Philip R. Olivieri, Anthony Reed, Karina Romero
  • Publication number: 20090176774
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: June 9, 2008
    Publication date: July 9, 2009
    Applicant: Amgen Inc.
    Inventors: Michele Potashman, Tae-Seong Kim, Steven Bellon, Shon Booker, Yuan Cheng, Joseph L. Kim, Andrew Tasker, Ning Xi, Shimin Xu, Jean-Christophe Harmange, George Borg, Matthew Weiss, Brian L. Hodous, Russell Graceffa, William H. Buckner, Craig E. Masse, Deborah Choquette, Matthew W. Martin, Julie Germain, Lucian V. DiPietro, Stuart C. Chaffee, Joseph J. Nunes, John L. Buchanan, David C. McGowan, Douglas A. Whittington, Gregory J. Habgood, Vinod F. Patel, Daniel La
  • Patent number: 7435823
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: January 24, 2005
    Date of Patent: October 14, 2008
    Assignee: Amgen Inc.
    Inventors: Michele Potashman, Tae-Seong Kim, Steven Bellon, Shon Booker, Yuan Cheng, Joseph L. Kim, Andrew Tasker, Ning Xi, Shimin Xu, Jean-Christophe Harmange, George Borg, Matthew Weiss, Brian L. Hodous, Russell Graceffa, William H. Buckner, Craig E. Masse, Deborah Choquette, Matthew W. Martin, Julie Germain, Lucian V. DiPietro, Stuart C. Chaffee, Joseph J. Nunes, John L. Buchanan, Gregory J. Habgood, David C. McGowan, Douglas A. Whittington, Daniel La, Vinod F. Patel